Literature DB >> 28592619

Incorporating Tumor Characteristics to the American Joint Committee on Cancer Breast Cancer Staging System.

Mariana Chavez-MacGregor1,2, Elizabeth A Mittendorf3, Christina A Clarke4,5, Daphne Y Lichtensztajn4, Kelly K Hunt3, Sharon H Giordano6,2.   

Abstract

BACKGROUND: The American Joint Committee on Cancer (AJCC) breast cancer staging system provides important prognostic information. The recently published eighth edition incorporates biological markers and recommends the use of a complex "prognostic stage." In this study, we assessed the relationship between stage, breast cancer subtype, grade, and outcome in a large population-based cohort and evaluated a risk score system incorporating tumor characteristic to the AJCC anatomic staging system.
MATERIALS AND METHODS: Patients diagnosed with primary breast cancer stage I-IV between 2005-2008 were identified in the California Cancer Registry. For patients with stage I-III disease, pathologic stage was recorded. For patients with stage IV disease, clinical stage was utilized. Five-year breast cancer specific survival (BCSS) and overall survival (OS) rates were determined for each potential tumor size-node involvement-metastases (TNM) combination according to breast cancer subtype. A risk score point-based system using grade, estrogen receptor, and human epidermal growth factor receptor 2 (HER2) status was designed to complement the anatomic AJCC staging system. Survival probabilities between groups were compared using log-rank test. Cox proportional hazards models were used.
RESULTS: Among 43,938 patients, we observed differences in 5-year BCSS and OS for each TNM combination according to breast cancer subtype. The most favorable outcomes were seen for hormone receptor-positive tumors followed closely by HER2-positive tumors, with the worst outcomes observed for triple negative breast cancer. Our risk score system separated patients into four risk groups within each stage category (all p < .05).
CONCLUSION: Our simple risk score system incorporates biological factors into the AJCC anatomic staging system, providing accurate prognostic information. IMPLICATIONS FOR PRACTICE: This study demonstrates that stage, but also breast cancer subtype and grade, define prognosis in a large population of breast cancer patients. It shows that a point-based risk score system that incorporates these biological factors provides refined stratification and information on prognosis, improving the anatomic American Joint Committee on Cancer (AJCC) staging system. In addition, the overall mortality and breast cancer specific mortality rates detailed here provide much-needed information about prognosis in the current era, refining the current AJCC staging. © AlphaMed Press 2017.

Entities:  

Keywords:  Breast cancer; Prognosis; Staging system; Tumor characteristics

Mesh:

Substances:

Year:  2017        PMID: 28592619      PMCID: PMC5679819          DOI: 10.1634/theoncologist.2017-0116

Source DB:  PubMed          Journal:  Oncologist        ISSN: 1083-7159


  37 in total

1.  Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.

Authors:  A S Coates; E P Winer; A Goldhirsch; R D Gelber; M Gnant; M Piccart-Gebhart; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2015-05-04       Impact factor: 32.976

2.  Combining Clinical and Pathologic Staging Variables Has Prognostic Value in Predicting Local-regional Recurrence Following Neoadjuvant Chemotherapy for Breast Cancer.

Authors:  Jose Vila; Mediget Teshome; Susan L Tucker; Wendy A Woodward; Mariana Chavez-MacGregor; Kelly K Hunt; Elizabeth A Mittendorf
Journal:  Ann Surg       Date:  2017-03       Impact factor: 12.969

3.  Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.

Authors:  W Fraser Symmans; Caimiao Wei; Rebekah Gould; Xian Yu; Ya Zhang; Mei Liu; Andrew Walls; Alex Bousamra; Maheshwari Ramineni; Bruno Sinn; Kelly Hunt; Thomas A Buchholz; Vicente Valero; Aman U Buzdar; Wei Yang; Abenaa M Brewster; Stacy Moulder; Lajos Pusztai; Christos Hatzis; Gabriel N Hortobagyi
Journal:  J Clin Oncol       Date:  2017-01-30       Impact factor: 44.544

4.  Adjuvant trastuzumab in HER2-positive breast cancer.

Authors:  Dennis Slamon; Wolfgang Eiermann; Nicholas Robert; Tadeusz Pienkowski; Miguel Martin; Michael Press; John Mackey; John Glaspy; Arlene Chan; Marek Pawlicki; Tamas Pinter; Vicente Valero; Mei-Ching Liu; Guido Sauter; Gunter von Minckwitz; Frances Visco; Valerie Bee; Marc Buyse; Belguendouz Bendahmane; Isabelle Tabah-Fisch; Mary-Ann Lindsay; Alessandro Riva; John Crown
Journal:  N Engl J Med       Date:  2011-10-06       Impact factor: 91.245

5.  Clinical relevance of TNM staging system according to breast cancer subtypes.

Authors:  Y H Park; S J Lee; E Y Cho; Y La Choi; J E Lee; S J Nam; J-H Yang; J H Shin; E Y Ko; B-K Han; J S Ahn; Y-H Im
Journal:  Ann Oncol       Date:  2011-01-17       Impact factor: 32.976

6.  Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004.

Authors:  Carol A Parise; Katrina R Bauer; Monica M Brown; Vincent Caggiano
Journal:  Breast J       Date:  2009-09-17       Impact factor: 2.431

7.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

Authors:  W Fraser Symmans; Florentia Peintinger; Christos Hatzis; Radhika Rajan; Henry Kuerer; Vicente Valero; Lina Assad; Anna Poniecka; Bryan Hennessy; Marjorie Green; Aman U Buzdar; S Eva Singletary; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  J Clin Oncol       Date:  2007-09-04       Impact factor: 44.544

8.  Rethinking TNM: breast cancer TNM classification for treatment decision-making and research.

Authors:  Umberto Veronesi; Giuseppe Viale; Nicole Rotmensz; Aron Goldhirsch
Journal:  Breast       Date:  2006-02       Impact factor: 4.380

9.  Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance of erbB-2 protein overexpression in primary breast cancer.

Authors:  S Paik; R Hazan; E R Fisher; R E Sass; B Fisher; C Redmond; J Schlessinger; M E Lippman; C R King
Journal:  J Clin Oncol       Date:  1990-01       Impact factor: 44.544

10.  Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.

Authors:  C Davies; J Godwin; R Gray; M Clarke; D Cutter; S Darby; P McGale; H C Pan; C Taylor; Y C Wang; M Dowsett; J Ingle; R Peto
Journal:  Lancet       Date:  2011-07-28       Impact factor: 79.321

View more
  25 in total

1.  Surgery of the Primary Tumor Offers Survival Benefits of Breast Cancer with Synchronous Ipsilateral Supraclavicular Lymph Node Metastasis.

Authors:  Qi-Tong Chen; Li-Yun Zeng; Deng-Jie Ouyang; Piao Zhao; Qiong-Yan Zou; Lei Pei; Na Luo; Wen-Jun Yi
Journal:  World J Surg       Date:  2020-04       Impact factor: 3.352

2.  Clinical significance of SPRY4-IT1 in efficacy and survival prediction in breast cancer patients undergoing neoadjuvant chemotherapy.

Authors:  Ang Zheng; Lin Zhang; Xinyue Song; Feng Jin
Journal:  Histol Histopathol       Date:  2019-10-22       Impact factor: 2.303

3.  Real-World Patterns of Everolimus Use in Patients with Metastatic Breast Cancer.

Authors:  Manvi Sharma; Zhigang Duan; Hui Zhao; Sharon H Giordano; Mariana Chavez-MacGregor
Journal:  Oncologist       Date:  2020-06-16

4.  Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx.

Authors:  Olga Kantor; Harold J Burstein; Tari A King; Steven Shak; Christy A Russell; Armando E Giuliano; Gabriel N Hortobagyi; Eric P Winer; Larissa A Korde; Joseph A Sparano; Elizabeth A Mittendorf
Journal:  Ann Surg Oncol       Date:  2022-07-27       Impact factor: 4.339

Review 5.  Preclinical Models to Study Obesity and Breast Cancer in Females: Considerations, Caveats, and Tools.

Authors:  Erin D Giles; Elizabeth A Wellberg
Journal:  J Mammary Gland Biol Neoplasia       Date:  2020-11-04       Impact factor: 2.673

6.  Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer.

Authors:  Anna Weiss; Mariana Chavez-MacGregor; Daphne Y Lichtensztajn; Min Yi; Audree Tadros; Gabriel N Hortobagyi; Sharon H Giordano; Kelly K Hunt; Elizabeth A Mittendorf
Journal:  JAMA Oncol       Date:  2018-02-01       Impact factor: 31.777

7.  Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer.

Authors:  Olga Kantor; Tari A King; Steven Shak; Christy A Russell; Armando E Giuliano; Gabriel N Hortobagyi; Harold J Burstein; Eric P Winer; Tanujit Dey; Joseph A Sparano; Elizabeth A Mittendorf
Journal:  J Natl Cancer Inst       Date:  2021-05-19       Impact factor: 13.506

8.  Untargeted Metabolomics of Breast Cancer Cells MCF-7 and SkBr3 Treated With Tamoxifen/Trastuzumab.

Authors:  Basma M Sharaf; Alexander D Giddey; Hasan Alniss; Hamza M Al-Hroub; Raafat El-Awady; Muath Mousa; Ahmed Almehdi; Nelson C Soares; Mohammad H Semreen
Journal:  Cancer Genomics Proteomics       Date:  2022 Jan-Feb       Impact factor: 4.069

9.  MicroRNA-671-3p inhibits the development of breast cancer: A study based on in vitro experiments, in-house quantitative polymerase chain reaction and bioinformatics analysis.

Authors:  Dan-Dan Xiong; Hao Chen; Rong-Quan He; Ai-Hua Lan; Jin-Cai Zhong; Gang Chen; Zhen-Bo Feng; Kang-Lai Wei
Journal:  Int J Oncol       Date:  2018-03-28       Impact factor: 5.650

10.  Evaluating the Prediction of Breast Cancer Survival Using Lymph Node Ratio.

Authors:  Man Hung; Julie Xu; Dominique Nielson; Jerry Bounsanga; Yushan Gu; Alec Roger Hansen; Maren Wright Voss
Journal:  J Breast Cancer       Date:  2018-08-28       Impact factor: 3.588

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.